The short answer
Retatrutide is commonly listed under CAS 2381089-83-2 with a molecular weight near 4,731 Da. Neither resolves to a PubChem record. Searches for retatrutide, LY3437943 and the CAS all return nothing. The identifiers come from supplier and reference sources rather than a primary database.
Key facts
- Development code
- LY3437943
- Reported CAS
- 2381089-83-2 (no PubChem record)
- Reported MW
- ~4,731.33 Da
- Reported formula
- C221H342N46O68 (sources disagree)
- PubChem entry
- None findable
- Primary reference
- Coskun, Cell Metab 2022 (PMID 35985340)
- Not to be confused with
- Tirzepatide, LY3298176
What is actually verifiable
Less than for any other compound in this library. Searching PubChem for retatrutide, LY3437943 or LY-3437943 returns nothing, and CAS 2381089-83-2 does not resolve there either. That is unusual for a compound with Phase 3 data and a filing date, and it means the molecular weight and formula quoted everywhere trace to supplier catalogues and reference aggregators rather than to a primary chemical database.
Sources disagree on the formula
The commonly quoted figure is 4,731.33 Da for C221H342N46O68. At least one reference source gives C228H350N48O66 at approximately 4,894.58 Da instead. Both cannot be right. Where a compound has a settled database entry this kind of disagreement does not arise, and its presence here is a direct consequence of the absent entry.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
The identifier this category had wrong
Until this revision, these articles cited PubChem CID 156588324 as retatrutide. That record returns 4813 Da for C225H348N48O68, and its synonyms include Zepbound, tirzepatidum and 'Tirzepatide sodium salt (LY3298176)'. It is tirzepatide. The compound retatrutide is most often compared against, and the one it most needs to be distinguished from. The citation has been removed.
What can be relied on instead
Coskun and colleagues published the discovery and characterisation of LY3437943 in Cell Metabolism in September 2022, and that paper is the primary structural reference. Eli Lilly's investor releases carry the trial data. ClinicalTrials.gov carries the registrations. These are verifiable in a way the chemical identifiers currently are not.
What this means practically
Treat the 4,731 Da figure as reported rather than verified, and be aware that a certificate quoting a different formula is not necessarily wrong. Mass spectrometry against whichever value a certificate claims is the only check available, and where a supplier and a reference source disagree there is no authoritative record to arbitrate between them.
Frequently asked questions
What is retatrutide's CAS number?
2381089-83-2 is the number commonly listed, though it does not resolve to a PubChem record.
Why is there no PubChem entry?
Not clear. Searches under the name, the development code and the CAS all return nothing, which is unusual for a compound at this stage of development.
Is CID 156588324 retatrutide?
No. That record is tirzepatide, its synonyms include Zepbound and LY3298176. It was cited in error here and has been removed.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubMedCoskun T et al., LY3437943, a novel triple glucagon, GIP and GLP-1 receptor agonist. Cell Metab 2022 (PMID 35985340)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · Tirzepatide, for contrast (CID 166567236)pubchem.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov · TRIUMPH-1 (NCT05929066). Retatrutide Phase 3 obesity trialclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-2 (NCT05929079). Retatrutide in type 2 diabetesclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-3 (NCT05882045). Retatrutide + established CVDclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-4 (NCT05931367). Retatrutide once weeklyclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-5 (NCT06662383). Retatrutide vs tirzepatideclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-6 (NCT06859268). Maintenance of weight reductionclinicaltrials.gov
- PubMedJastreboff AM et al., Triple-Hormone-Receptor Agonist Retatrutide for Obesity. NEJM 2023 (PMID 37366315)pubmed.ncbi.nlm.nih.gov
- PubMedRosenstock J et al., Retatrutide for people with type 2 diabetes. Lancet 2023 (PMID 37385280)pubmed.ncbi.nlm.nih.gov
- DrugBankDrugBank · Retatrutide (DB18435)go.drugbank.com
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More Retatrutide Research articles
- How the Incretin Field Got HereExenatide from lizard venom, liraglutide's fatty acid, semaglutide's weekly dosing, then multi-agonism. Each generation solved the previous one's limit.
- Retatrutide Storage and StabilityA lipidated 39-mer is more surface-active than most peptides. Why foaming matters more here, and what the fatty acid changes about handling.
- Retatrutide Molecular Weight4,731.33 Da is the figure everyone quotes. It comes from supplier sources rather than a primary database, and at least one reference gives a different formula.
- Retatrutide in the Published LiteratureA small literature of unusually high quality - Cell Metabolism, NEJM, the Lancet - and a Phase 3 programme of more than 5,800 participants.
- What Is the TRIUMPH Trial Programme?TRIUMPH is Eli Lilly's Phase 3 programme for retatrutide: 5,800+ participants. TRIUMPH-1 reported 28.3% mean weight reduction at 80 weeks in May 2026.